See the Harm | NEJM
Medical students are faced with a dilemma: for them to learn, enough people have to get sick, with varied and sometimes terrible illnesses. In order to do no harm, they first need to see some harm.
Related Articles
The Plight of “Dual Noneligible” People in the United States | NEJM
Policy solutions are needed to cover adequate health care for the approximately 1.1 million older, low-income adults in the United States who are undocumented immigrants.
FDA Grants Fast Trask Designation to Invikafusp Alfa for Advanced Colorectal Cancer
Invikafusp alfa (STAR0602; Marengo Therapeutics Inc) is being investigated as a treatment for advanced colorectal cancer with high tumor mutational burden.
ACP Hospitalist
ACP Hospitalist provides hospital-based physicians with news and information about the practice of hospital medicine.
Using a novel smartphone app to track noise and vibration exposure during neonatal ambulance transport
Objective To assess the utility of a bespoke smartphone app to map noise and vibration exposure across neonatal road ambulance journeys. Design and setting Prospective…
A Comparison of Peripherally Inserted Central Catheter Materials | NEJM
New catheter materials for peripherally inserted central catheters (PICCs) may reduce the risk of device failure due to infectious, thrombotic, and catheter occlusion events. However,…
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM
Talquetamab (anti–G protein–coupled receptor family C group 5 member D) and teclistamab (anti–B-cell maturation antigen) are bispecific antibodies that activate T cells by targeting CD3…
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma | NEJM
Twelve hundred ninety-six patients with resected colon cancer that either was locally invasive (Stage B2) or had regional nodal involvement (Stage C) were randomly assigned…
AI Improves Breast Cancer Screening and Detection Rates in Real-World Study
Inclusion of AI improved detection and reduced instances of false-positive test results.